CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
Drug Approval

CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology

South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe

  • By IPP Bureau | November 30, 2022

CPHI & PMEC India 2022, organized by Informa Markets in India, commenced yesterday at the India Expo Centre, Greater Noida, Delhi – NCR. The show provided a unique opportunity to all the stakeholders to discuss the entire range of pharma machinery, analytical instruments, laboratory technologies and equipment’s, ancillaries, ingredients and more in a hybrid format.

The 15th edition of CPHI & PMEC India on the theme #GetPharmore with Pharmore opportunities and Pharmore connections, witnessed one of the largest gatherings of industry experts, leading manufacturers, buyers’ community, policy advisors, and other key stakeholders.

The grand inauguration ceremony marked by the presence of key dignitaries Dr. Veeramani S.V, Vice-Chairman Pharmexcil, Alessandro Liberatori, Director, Italian Trade Commissions, AVPS Chakravarthi, Ambassador – World Packaging Organisation & Board Member Pharmexcil, Bodh Raj Sikri, Chairman, Federation of Pharmaceutical Entrepreneurs, Margaret Ma, President & CEO Informa Markets Asia, Chris Eve, Executive. Vice President, Informa Markets Asia and Yogesh Mudras, Managing Director, Informa Markets in India.

Speaking on the sidelines of inaugural, Ravi Uday Bhaskar, Director General, Pharmexcil said, “The Indian pharmaceutical exports have recorded an impressive growth of approximately 5% in the current financial year (April-Oct 2022). Despite having global challenges, we have exported over USD 25 billion in the biggest market, which means about 30% of our exports are going to the US. At CPHI & PMEC India, we received a great response with more than 100 Pharma companies and 100+ stalls and huge number of bookings. We are looking forward to participate in the next edition, with a larger floor space and a market size in excess of USD 27 billion for FY23.”

Offering the industry perspective, Dr. Veeramani S.V, Vice-Chairman Pharmexcil, said “There is a strong push from the Government towards creating an ecosystem for innovation so that India can become a leader in discovery of drugs and medical technology. Currently, the Indian Pharmaceutical market is valued at around USD 50 billion, out of which almost USD 25 billion constitutes the export market. CPHI & PMEC India 2022 has provided an unbiased and vocal platform which brings all the key stakeholders on one table and contribute towards nation’s target, with the vision that the domestic market will touch USD 130 billion by 2030 out of which over 60% will only be exports. “

Addressing the opportunities in this sector, Mudras, said, “India’s pharmaceutical sector has done far more than prove itself in terms of manufacturing volumes and emerged as a life sciences leader within the post-pandemic order. India's pharmaceutical sector is a US$50 billion industry and is anticipated to grow to at least US$150 billion in less than a decade. The government is also developing new strategies to strengthen the sector which has led to the creation of innovation hubs making India an ideal testing ground for innovations in digital health. 

“Our show CPHI & PMEC India has demonstrated excellence in further supporting the industry by curating highly effective platforms for showcasing technology solutions, knowledge sharing, networking, and advocacy. We are confident that the 15th edition of the show and the other events surrounding it will deliver unprecedented success for all participants of this industry. Furthermore, they will play their role in encouraging the ‘Make in India’ credo of the Government that aims to facilitate investment, foster innovation, enhance skill development, protect intellectual property & build best-in-class manufacturing infrastructure.”

Upcoming E-conference

Other Related stories